A first-of-its-kind study in an article in the journal Multiple Sclerosis and Related Disorders states that patients with MS may safely be treated with placenta-derived cells. Safety was determined, and the next step is efficacy.
Lead investigator Fred Lublin, MD, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, and Professor of Neurology at Icahn School of Medicine at Mount Sinai, stated that “we could be looking at a new frontier in treatment for” MS. In the small study of 16 MS patients, no subjects showed worsening of symptoms, which is always a risk due to immune system altering, and the majority of patients had improved or stable disability levels.
To read the article, click here.